Children's Hospital at Montefiore, Division of Pediatric Rheumatology, Department of Pediatrics, 3415 Bainbridge Avenue, Bronx, NY 10467, USA.
Expert Opin Pharmacother. 2013 Jun;14(8):975-89. doi: 10.1517/14656566.2013.783569. Epub 2013 Mar 26.
Juvenile idiopathic arthritis (JIA) is the most common chronic rheumatic disease in childhood. Therapeutic advances in the treatment of JIA are occurring at a rapid rate, resulting in more ambitious therapeutic goals and increasing numbers of children experiencing complete clinical remission.
The purpose of this review is to summarize the available treatments for the management of arthritis and systemic features in children with JIA, including current evidence supporting the safety and efficacy of biologic agents and future therapeutic approaches.
With advances in pharmacotherapy, physical and functional outcomes in children with JIA have improved immensely. The establishment of research consortia among the pediatric rheumatology community has allowed for large controlled studies and enabled a better understanding of the safety and efficacy of these therapeutic agents in children. Long-term safety data remain limited and thus longer, larger safety studies are warranted.
幼年特发性关节炎（JIA）是儿童中最常见的慢性风湿性疾病。JIA 的治疗在迅速发展，这导致了更具野心的治疗目标和更多的儿童经历完全临床缓解。
本文旨在总结 JIA 儿童关节炎和全身症状管理的现有治疗方法，包括支持生物制剂安全性和有效性的现有证据，以及未来的治疗方法。
随着药物治疗的进步，JIA 儿童的身体和功能结果有了巨大改善。儿科风湿病学界的研究联盟的建立使得大型对照研究成为可能，并使人们更好地了解这些治疗药物在儿童中的安全性和疗效。长期安全性数据仍然有限，因此需要进行更长、更大规模的安全性研究。
